06 June 2024
06 June 2024
ArriVent will pay up to $615.5m in combined upfront and potential milestone payments to Alphamab.
Keeping high-qualified, experienced clinical trial staff on board plays a crucial role in bringing new drugs to market.
The facility expansion is part of the company’s plan to meet surging global demand for critical drugs.
The company anticipates a successful launch and distribution of Enmetazobactam and its combination with Cefepim to treat serious infections.
Experts dig into the evolving EU regulatory landscape to identify the key details that could change this space.
The company plans to launch a Phase I/II study of BE-101 in adults with haemophilia B in the second half of this year.
Osteal will seek FDA approval upon completion of its Phase III trial later this year.
While the potential for using AI to develop mRNA therapeutics is now a real possibility, accurate and diverse data is needed to make it a reality.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
